(Q28071551)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

3 references

8 September 2020

14 September 2020

New investigational drugs with single-agent activity in multiple myeloma (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

6 references

22 March 2019

3 April 2019

17 June 2019

6 August 2019

8 September 2020

14 September 2020

pharmaceutical preparation

1 reference

6 August 2019

investigational drugs

1 reference

8 September 2020

1 reference

14 September 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

A M Rajan

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

1 reference

29 July 2016

8 references

22 March 2019

3 April 2019

17 June 2019

6 August 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

8 September 2020

14 September 2020

7 references

22 March 2019

3 April 2019

17 June 2019

6 August 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

8 September 2020

14 September 2020

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

e451

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

20 March 2020

copyright license

6 references

22 March 2019

3 April 2019

17 June 2019

6 August 2019

8 September 2020

on focus list of Wikimedia project

14 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Interpretation of cytogenetic results in multiple myeloma for clinical practice

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Targeting the Pim kinases in multiple myeloma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Targeting the kinesin spindle protein: basic principles and clinical implications.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Improved survival in multiple myeloma and the impact of novel therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

A phase 2 study of bortezomib in relapsed, refractory myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Antitumor activity of thalidomide in refractory multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5030378

Is the open mouth mightier than the needle?

29 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

Sequence and structure relationships within von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

"A fortuitous combination of circumstances".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.53

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27471867

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/27471867

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BCJ.2016.53

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 March 2020

1004473413

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27471867%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

27471867

2 references